TWP
SRPT icon

Tempus Wealth Planning’s Sarepta Therapeutics SRPT Stock Holding History

Tempus Wealth Planning’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,658
Closed -$353K – 287
2025
Q2 		$353K Buy
20,658
+17,070
+476% +$728K 0.09% 191
2025
Q1 		$229K Buy
+3,588
New +$378K 0.07% 233

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Tempus Wealth Planning's SRPT Position: Q3 2025 in Review

Tempus Wealth Planning sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 20,658 shares — an estimated $353K sold.

Tempus Wealth Planning first reported a position in SRPT in Q1 2025 and held it in 2 quarters. The position peaked at $353K in Q2 2025. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Tempus Wealth Planning reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tempus Wealth Planning sold 20,658 Sarepta Therapeutics shares in Q3 2025, an estimated $353K.
  • Tempus Wealth Planning first reported a position in Sarepta Therapeutics in Q1 2025 and held it in 2 quarters.
  • Tempus Wealth Planning's Sarepta Therapeutics position peaked at $353K in Q2 2025.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Tempus Wealth Planning's 13F filing for Q3 2025, filed 6 Nov 2025.